Novo Nordisk Says Its Rybelsus Oral Semaglutide Reduces Risk of Major Adverse Cardiovascular Events
Catalent's Maselli to Continue as CEO Post Novo Holdings Deal Close
Novo Nordisk's Oral Cardiovascular Drug Trial Achieves Primary Objective
Novo Nordisk Announced SOUL Cardiovascular Outcomes Trial Achieved Its Primary Objective By Demonstrating A Statistically Significant And Superior Reduction In MACE Of 14% For People Treated With Oral Semaglutide Vs Placebo
'FDA Won't Take Action Against GLP-1 Compounders As It Rethinks Tirzepatide Shortage' - Endpoints News
European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock